Recruiting
NA
INTERVENTIONAL
NCT07226947
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Interventions
Name:
Smartwatch activity and body composition monitor
Type:
DEVICE
Description:
Participants will be provided a smartwatch to monitor their exercise and body composition
Name:
General guidance on recommended exercise
Type:
BEHAVIORAL
Description:
Participants will receive general guidance on recommended exercise
Primary Outcomes
Measure:
Lean mass (kg)
TimeFrame:
6 months
Description:
Dual-energy X-ray absorptiometry (DXA) body composition measure
Trial Information
NCT ID
NCT07226947
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Massachusetts General Hospital
Last Updated
December 15, 2025